London. Antibodies produced as a result of infection with one type of the virus SARS-CoV-2 variant that causes COVID-19 are able to prevent other variants from entering host cells and replicate. This has come to the fore in a research. Understanding how certain variants may be able to trigger an effective antibody response against other variants may help inform future vaccine design, said the team from the Francis Crick Institute and University College London Hospitals NHS Foundation Trust (UCLH). can help.
In their study, published in the journal eLife, the scientists analyzed blood samples collected from patients who were previously infected with COVID-19 and admitted to UCLH at different points in the onset of the pandemic and for other reasons. Was. Also samples from health care workers there as well as samples collected from patients were analyzed.
They identified COVID-19 antibodies in the blood and were tested in the laboratory to see if the antibodies produced after one type of infection were able to bind to and neutralize the other types.
The study included: the original strain first discovered in Wuhan, China, the dominant strain (D614G), alpha (B117) that originated in Europe during the first wave in April 2020, first discovered in the UK, and for the first time in South Africa Discovered in beta (b1351).
The researchers found that the antibodies produced by the alpha variant are not able to neutralize the original or D614G strains as effectively as compared to neutralizing the alpha variants.
The antibody produced against infection with the D614G strain is able to neutralize both the alpha and the original strains to the same level as D614G.
Both the alpha and D614G strains produced antibodies that were not able to effectively neutralize the beta strain.
There are many components of the immune system that decide how well a person can be protected from future disease. This includes memory B cells and T cells that equip the immune system to deal with emerging threats. As a result, these findings do not necessarily mean that people who were infected with specific forms are less protected than others.
Kevin Ng, a doctoral student at the Crick-based Retroviral Immunology Laboratory, said, “It is important to note that most people who have been infected with the virus will not know what they were infected with, and it is important that the vaccine is used. takes every opportunity to be eligible, because we know they are somehow effective against all known variants of the people.” (IANS)
read this also – Click to read the news of your state / city before the newspaper
.
